Drugmaker Price Hikes Continue Despite Trump Deals, Senate Report Finds
Despite President Trump’s assertions that his deals with drugmakers would lower prescription drug prices, a Senate Democratic report indicates prices have continued to rise, with some medications experiencing sharp increases. Companies that entered into agreements with the administration have reportedly raised the cost of hundreds of drugs and launched new ones at an average annual price of $353,000. These price hikes affect critical treatments such as gene therapies and cancer medications, while the companies themselves have seen significant profit increases. The report raises concerns about the effectiveness and transparency of the administration’s pricing strategies, with critics arguing that these efforts may have primarily benefited drug companies rather than consumers.
John Q. Hosedrinker